comparemela.com

Latest Breaking News On - Prnewswire akeso - Page 2 : comparemela.com

Akeso Announced 2023 Interim Results: First Profit, Growing Sales of PD-1/CTLA-4 Bispecific Antibody and Priority Review of PD-1/VEGF

During the reporting period, Akeso s revenue was RMB3,676.9 million, an increase of 2,154.4% from 2022H1; Akeso recorded a profit of RMB2,489.5 million..

United statesMichelle xiaPrnewswire akesoSummit therapeutics incAkeso incChina national medical products administrationSummit therapeuticsNew drug applicationDrug evaluationNational medical products administration

Akeso s Ivonescimab (PD-1/VEGF Bispecific Antibody, AK112) Granted Breakthrough Therapy Designation for I-O Resistance NSCLC Patients in China

AK112 has now been granted three Breakthrough Therapy Designations for NSCLCThe only drug candidate granted Breakthrough Therapy Designation for I.

Akeso biopharmaPrnewswire akesoChina national medical products administrationAkeso incBreakthrough therapy designationsBreakthrough therapy designationIo resistanceDrug evaluationNon small cell lung carcinomaTherapy designations

vimarsana © 2020. All Rights Reserved.